Loading...
•
Jun 30, 2024
OrthoPediatrics Q2 2024 Earnings Report
Reported a record second quarter with a 33% year-over-year revenue increase, driven by growth in Trauma & Deformity and Scoliosis products, as well as the addition of Boston O&P.
Key Takeaways
OrthoPediatrics Corp. announced its Q2 2024 financial results, achieving record revenue of $52.8 million, a 33% increase compared to the same period last year. The company helped a record 32,000 children, marking a 52% increase from Q2 2023. They reaffirmed their full-year 2024 revenue guidance of $200.0 million to $203.0 million.
Helped a record 32,000 children in Q2 2024, a 52% increase year-over-year.
Generated record total revenue of $52.8 million in Q2 2024, up 33% year-over-year.
Worldwide Trauma & Deformity revenue grew 37%, Scoliosis revenue grew 26%, and Sports Medicine/Other revenue increased 17% year-over-year.
Received Breakthrough Device Designation from FDA for eLLiTM Growing Rod System.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma & Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company reiterated its revenue guidance of $200.0 million to $203.0 million, representing growth of 34% to 36% over 2023 revenue. The Company reiterated annual set deployment to be less than $20.0 million and reiterated $8.0 million to $9.0 million of Adjusted EBITDA for the full year of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income